Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues.
Robbie G MajznerJason S SimonJoseph F GrossoDaniel MartinezBruce R PawelMariarita SantiMelinda S MerchantBirgit GeoergerImene HezamVirginie MartyPhillippe VielhMads DaugaardPoul H SorensenCrystal L MackallJohn M MarisPublished in: Cancer (2017)
A subset of diagnostic pediatric cancers exhibit PD-L1 expression, whereas a much larger fraction demonstrates infiltration with tumor-associated lymphocytes. PD-L1 expression may be a biomarker for poor outcome in neuroblastoma. Further preclinical and clinical investigation will define the predictive nature of PD-L1 expression in childhood cancers both at diagnosis and after exposure to chemoradiotherapy. Cancer 2017;123:3807-3815. © 2017 American Cancer Society.